NR1H4 and metabolic dysfunction-associated steatohepatitis: In addition, TβMCA is a known antagonist of FXR in rodents (Li et al., 2013), consistently, we found that fecal TβMCA in BBR-treated mice was decreased, indicating the intestinal FXR activation might be the critical mechanism underlying the efficacy of BBR on NASH.